References
- Qiao, R.; Jiang, Y. Progress on Cutaneous Adverse Events and Management of Common Molecular Targeted Antitumor Drugs. Chin. J. Dermatovencereol. 2021, 35, 1054–1057. DOI: https://doi.org/10.13735/j.cjdv.1001-7089.
- Sureda, A.; Martorell, M.; Capó, X.; Monserrat-Mesquida, M.; Quetglas-Llabrés, M. M.; Rasekhian, M.; Nabavi, S. M.; Tejada, S. Antitumor Effects of Triterpenes in Hepatocellular Carcinoma. Curr. Med. Chem., 2021, 28(13), 2465–2484. DOI: https://doi.org/10.2174/0929867327666200602132000.
- Gregorić, T.; Sedić, M.; Grbčić, P.; Tomljenović Paravić, A.; Kraljević Pavelić, S.; Cetina, M.; Vianello, R.; Raić-Malić, S. Novel Pyrimidine-2,4-Dione-1,2,3-Triazole and Furo[2,3-d]Pyrimidine-2-one-1,2,3-Triazole Hybrids as Potential Anti-Cancer Agents: Synthesis, Computational and X-ray Analysis and Biological Evaluation. Eur. J. Med. Chem. 2017, 125, 1247–1267. DOI: https://doi.org/10.1016/j.ejmech.2016.11.028.
- Naresh Kumar, R.; Poornachandra, Y.; Nagender, P.; Mallareddy, G.; Ravi Kumar, N.; Ranjithreddy, P.; Ganesh Kumar, C.; Narsaiah, B. Synthesis of Novel Trifluoromethyl Substituted Furo[2,3-b]Pyridine and Pyrido[3',2':4,5]- Furo[3,2-d]Pyrimidine Derivatives as Potential Anticancer Agents. Eur. J. Med. Chem. 2016, 108, 68–78. DOI: https://doi.org/10.1016/j.ejmech.2015.11.007.
- Russo, F.; Santagati, M.; Santagati, A.; Caruso, A.; Trombartore, S.; Amico, R. M. New Nitrogenous Polycyclic Systems. Synthesis and Pharmacological Properties of Benzofuro and Thienothiadiazolopyrimidine Derivatives. Farmaco. Ed. Sci. 1983, 38, 762–774.
- Hossam, M.; Lasheen, D. S.; Ismail, N.; Esmat, A.; Mansour, A. M.; Singab, A.; Abouzid, K. Discovery of Anilino-Furo[2,3-d]Pyrimidine Derivatives as Dual Inhibitors of EGFR/HER2 Tyrosine Kinase and Their Anticancer Activity. Eur. J. Med. Chem. 2018, 144, 330–348. DOI: https://doi.org/10.1016/j.ejmech.2017.12.022.
- Zhao, A.; Gao, X.; Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Geng, M.; Zhang, A. A. Discovery of Novel c-Met Kinase Inhibitors Bearing a Thieno[2,3-d]Pyrimidine or Furo[2,3-d]Pyrimidine Scaffold. Bioorg. Med. Chem. 2011, 19, 3906–3918. DOI: https://doi.org/10.1016/j.bmc.2011.05.038.
- Hou, J. Z.; Xi, Z. Q.; Niu, J.; Li, W.; Wang, X.; Liang, C.; Sun, H.; Fang, D.; Xie, S. Q. Inhibition of PIKfyve Using YM201636 Suppresses the Growth of Liver Cancer via the Induction of Autophagy. Oncol. Rep. 2019, 41, 1971–1979. DOI: https://doi.org/10.3892/or.2018.6928.
- Devambatla, R. K. V.; Choudhary, S.; Ihnat, M.; Hamel, E.; Mooberry, S. L.; Gangjee, A. Design, Synthesis and Preclinical Evaluation of 5-methyl-N4-Aryl-Furo[2,3-d]Pyrimidines as Single Agents with Combination Chemotherapy Potential. Bioorg. Med. Chem. Lett. 2018, 28, 3085–3093. DOI: https://doi.org/10.1016/j.bmcl.2018.07.039.
- Hou, N.; Man, J. H.; Wang, X. Y.; He, S.; Li, Q.; Hu, Y. G. Efficient Synthesis and Biological Evaluation of 2,4-Diamino-Thieno[2,3-d]Pyrimidine Derivative. ChemistrySelect. 2019, 4, 4901–4904. DOI: https://doi.org/10.1002/slct.201900123.
- Li, Q.; Chen, Y. M.; Hu, Y. G.; Luo, X.; Shun Ko, J. K.; Cheung, C. W. Synthesis and Biological Activity of Fused Furo[2,3-d]Pyrimidinone Derivatives as Analgesic and Antitumor Agents. Res. Chem. Intermed. 2016, 42, 939–949. DOI: https://doi.org/10.1007/s11164-015-2064-8.
- He, S.; Ma, J.; Li, F.; Hu, Y. Synthesis of Fused Tetracyclic Benzo[4,5]- Furo[3,2-d]Pyrimidin- 4(3H)-Ones Derivatives Containing Thiadiazole/Oxazolidine/Triazole/Triazinanone Moieties. J. Heterocyclic. Chem. 2021, 58, 206–211. DOI: https://doi.org/10.1002/jhet.4160.
- Hu, Y. G.; Wang, Y.; Du, S. M.; Chen, X. B.; Ding, M. W. Efficient Synthesis and Biological Evaluation of Some 2,4-diamino-furo[2,3-d]pyrimidine derivatives. Bioorg. Med. Chem. Lett. 2010, 20, 6188–6190. DOI: https://doi.org/10.1016/j.bmcl.2010.08.122.
- Case, D. A.; Betz, R. M.; Cerutti, D. S.; Kollman, P. A. Amber 2016: University of California: San Francisco, 2016.
- Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.; Simmerling, C. Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 2015, 11, 3696–3713. DOI: https://doi.org/10.1021/acs.jctc.5b00255.
- Price, D. J.; Brooks, C. L. 3rd A Modified TIP3P Water Potential for Simulation with Ewald Summation. J. Chem. Phys. 2004, 121, 10096–10103. DOI: https://doi.org/10.1063/1.1808117.
- Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. Comput. Phys. 1977, 23, 327–341. DOI: https://doi.org/10.1016/0021-9991(77)90098-5.
- Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations. J. Chem. Inf. Model. 2011, 51, 69–82. DOI: https://doi.org/10.1021/ci100275a.
- Sitkoff, D.; Sharp, K. A.; Honig, B. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models. J. Phys. Chem. 1994, 98, 1978–1988. DOI: https://doi.org/10.1021/j100058a043.
- Pan, Y. M.; Gao, D. Q.; Zhan, C. G. Modeling the Catalysis of anti-Cocaine Catalytic Antibody: Competing Reaction Pathways and Free Energy Barriers. J. Am. Chem. Soc. 2008, 130, 5140–5149. DOI: https://doi.org/10.1021/ja077972s.
- Wu, E. L.; Mei, Y.; Han, K.; Zhang, J. Z. Quantum and Molecular Dynamics Study for Binding of Macrocyclic Inhibitors to Human Alpha-Thrombin. Biophys. J. 2007, 92, 4244–4253. DOI: https://doi.org/10.1529/biophysj.106.099150.
- Wu, E. L.; Han, K.; Zhang, J. Z. Selectivity of Neutral/Weakly Basic P1 Group Inhibitors of Thrombin and Trypsin by a Molecular Dynamics Study. Chemistry. 2008, 14, 8704–8714. DOI: https://doi.org/10.1002/chem.200800277.